

Thank you for your comments, which we feel have made our paper both more interesting and more relevant.

**Reviewer's code 00188507:**

Comments to the authors:

The authors reviewed the toxicity of immunotherapy on the gastrointestinal tract. The information summarized here are useful for the next era of immune oncology, and the draft is actually well written. The authors may want to include the toxicity of anti-CTLA-4, anti-PD1, and anti-PDL1 antibody on the biliary tract which is connected to the duodenum and should be considered as a part of the tract. They may want to include the references of current reports: 1. PMID- 30033637, Ogawa K, et al. 2. Doherty GJ, et al. ESMO Open. 2017; 2: e000268. 3. Cho JH, et al. J Thorac Oncol 2018; 13: e34-e36. 4. Kashima J, et al. Cancer Immunol Immunother. 2018; 67: 61-65.

**Reply:** We have added a section on biliary involvement, given that our review focuses more on the endoscopic effects of immunotherapy than on its potential clinical and laboratory effects. We have taken some of the references you propose into account.

**Reviewer's code 02953383:**

Comments to the authors:

1. Title: May be more specific, such as "Endoscopic Evaluation of Immunotherapy-Induced Gastrointestinal Toxicity"

**Reply:** We have changed the title, as requested.

2. Figure legend with brief description of the characteristics of various lesions may be helpful for the readers to better understand the figures. In addition, since the topic of the endoscopic evaluation, more high-resolution endoscopic figures of other lesions (i.e. upper GI lesions) may increase the value of this

manuscript. Some histological figures obtained during endoscopic biopsy would also make the manuscript more informative.

**Reply:** We have modified the description of the lesions. We also provide more images of upper digestive involvement.

3. What did the authors mean by “serial biopsy” during endoscopy? Please clarify.

**Reply:** We have modified the term “serial biopsy”.

4. It seems that the histological findings are also non-specific. How could they be used to confirm the diagnosis as mentioned in the conclusion?

**Reply:** We have extended our description of the histologic finding. We have also modified the conclusion to make it more comprehensible.

5. Please cite the original references for each important statement in the manuscript, such as the treatment suggestions in the section pf “HOW SHOULD THE DISEASE BE TREATED?”

**Reply:** We have added the original references.

6. Please add a brief section on the Pathophysiology of the GI toxicity.

**Reply:** We have added a brief section on the pathophysiology of GI toxicity.

**Reviewer’s code 02573214:**

Comments to the autors:

He work does not present any kind of originality, but it is a good review of the present “state of art” about endoscopic evaluation of immunotherapy-induced toxicity.

**Reply:** Thank you for your kind comment.